One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.
作者信息
Jain A B, Fung J J, Todo S, Reyes J, Selby R, Irish W, Doyle H, Abu-Elmagd K, Casavilla A, Nour B
机构信息
Pittsburgh Transplant Institute, University of Pittsburgh Health Science Center, Pennsylvania.
出版信息
Transplant Proc. 1995 Feb;27(1):1099-104.
Abstract
摘要
相似文献
1
One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.在使用FK506的情况下进行的1000例连续原位肝移植：生存率和不良事件。
Transplant Proc. 1995 Feb;27(1):1099-104.
2
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults.110例成人在使用FK 506情况下进行的连续原位肝移植。
Transplant Proc. 1991 Feb;23(1 Pt 2):1397-402.
3
Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients.接受他克莫司治疗的婴儿、儿童、成人及老年人肝移植：1000例连续患者的长期结果、生存率及不良事件
Transplant Proc. 1998 Jun;30(4):1403-4. doi: 10.1016/s0041-1345(98)00290-5.
4
Impact of donor and recipient gender on liver transplantation.供体和受体性别对肝移植的影响。
Transplant Proc. 1997 Dec;29(8):3431-2. doi: 10.1016/s0041-1345(97)00966-4.
5
Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.
Transplant Proc. 1995 Feb;27(1):1121-3.
6
Cyclosporine A reduction and withdrawal in liver transplantation: a risk-benefit analysis.肝移植中环孢素A的减量与停用：风险效益分析
Transplant Proc. 1997 Nov;29(7):2819-21. doi: 10.1016/s0041-1345(97)00691-x.
7
Outcome of patients undergoing orthotopic liver transplantation with elderly donors (over 60 years).
Transplant Proc. 1997 Dec;29(8):3289-90. doi: 10.1016/s0041-1345(97)00914-7.
8
FK 506 treatment of intractable rejection after liver transplantation.FK506治疗肝移植后难治性排斥反应
Transplant Proc. 1993 Aug;25(4):2686-7.
9
Intensive care after orthotopic liver transplantation.原位肝移植后的重症监护
Transplant Proc. 1994 Aug;26(4):2246-7.
10
Transient hyperphosphatasemia after liver transplantation in infancy.婴儿肝移植后的短暂性高磷酸酶血症
Transplant Proc. 1996 Oct;28(5):2847.
引用本文的文献
1
Posterior Reversible Encephalopathy Syndrome Associated with Tacrolimus in Cardiac Transplantation.心脏移植中与他克莫司相关的后部可逆性脑病综合征
Case Rep Cardiol. 2021 Jun 24;2021:9998205. doi: 10.1155/2021/9998205. eCollection 2021.
2
PREVALENCE AND RISK FACTORS OF HYPERKALEMIA AFTER LIVER TRANSPLANTATION.肝移植术后高钾血症的患病率及危险因素
Arq Bras Cir Dig. 2018 Jun 21;31(1):e1357. doi: 10.1590/0102-672020180001e1357.
3
Hyponatremia during administration of tacrolimus in an allogeneic bone marrow transplant recipient.一名异基因骨髓移植受者在使用他克莫司期间出现低钠血症。
Int J Hematol. 2003 Oct;78(3):268-9. doi: 10.1007/BF02983807.
4
Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.他克莫司能否为初次肝移植后的慢性排斥反应提供几乎完全的预防？1048例肝移植患者的风险及预后因素分析，平均随访6年。
Liver Transpl. 2001 Jul;7(7):623-30. doi: 10.1053/jlts.2001.25364.
5
What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.关于在他克莫司免疫抑制下进行的原位肝移植，我们了解到了什么？对首批1000例患者的长期随访。
Ann Surg. 1999 Sep;230(3):441-8; discussion 448-9. doi: 10.1097/00000658-199909000-00016.
6
Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients.接受他克莫司治疗的婴儿、儿童、成人及老年人肝移植：1000例连续患者的长期结果、生存率及不良事件
Transplant Proc. 1998 Jun;30(4):1403-4. doi: 10.1016/s0041-1345(98)00290-5.
7
Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation.他克莫司。其在器官移植管理中的药理学及临床疗效的最新进展。
Drugs. 1997 Dec;54(6):925-75. doi: 10.2165/00003495-199754060-00009.
8
Gastrointestinal bleeding after liver transplantation.肝移植术后胃肠道出血
Transplantation. 1997 Jan 15;63(1):60-7. doi: 10.1097/00007890-199701150-00012.
9
A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results.一项关于他克莫司（FK 506）用于临床心脏移植的前瞻性试验：中期结果。
J Thorac Cardiovasc Surg. 1996 Apr;111(4):764-72. doi: 10.1016/s0022-5223(96)70336-7.
本文引用的文献
1
Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era.肝移植术前风险评估：对2376例UW时代病例的多因素分析
Transplant Proc. 1997 Feb-Mar;29(1-2):454-5. doi: 10.1016/s0041-1345(96)00199-6.
2
3
FK 506 for liver, kidney, and pancreas transplantation.用于肝脏、肾脏和胰腺移植的FK 506。
Lancet. 1989 Oct 28;2(8670):1000-4. doi: 10.1016/s0140-6736(89)91014-3.
4
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls.肝移植受者从环孢素转换为基于FK 506的免疫抑制：益处与风险。
Transplant Proc. 1991 Feb;23(1 Pt 1):14-21.
5
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.FK506 作用下原位肝移植术后排斥反应的发生率及治疗情况
Transplant Proc. 1991 Feb;23(1 Pt 2):928-30.
6
7
Infections in adult liver transplant patients under FK 506 immunosuppression.接受FK 506免疫抑制治疗的成年肝移植患者的感染情况。
Transplant Proc. 1991 Feb;23(1 Pt 2):1501-3.
8
The question of FK 506 nephrotoxicity after liver transplantation.肝移植后FK 506的肾毒性问题。
Transplant Proc. 1991 Feb;23(1 Pt 2):1444-7.
9
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults.110例成人在使用FK 506情况下进行的连续原位肝移植。
Transplant Proc. 1991 Feb;23(1 Pt 2):1397-402.
10
Liver, kidney, and thoracic organ transplantation under FK 506.在使用FK506情况下的肝脏、肾脏及胸部器官移植。
Ann Surg. 1990 Sep;212(3):295-305; discussion 306-7. doi: 10.1097/00000658-199009000-00008.
Zotero 插件